Italian guidelines for the management of adult individuals with overweight and obesity and metabolic comorbidities that are resistant to behavioral treatment
Proton pump inhibitors may help with acid-related symptoms
This is the largest treatment benefit weve ever seen for that endpoint in this patient population with any drug, Kosiborod told CNN ahead of the European Society of Cardiology meeting in Amsterdam, where the results are being presented
Patients with Type 2 diabetes who have inadequate glycemic control, those with obesity (BMI 30) or overweight individuals with comorbidities, and adults with established cardiovascular disease benefit most from Semaglutide therapy
While GLP-1 medications can drive more rapid weight loss (3-4+ pounds weekly), slower is much better for body composition and muscle preservation
Ongoing Support and Follow-Up: Regular follow-up appointments through Ogaei ensure your treatment remains effective, allow for dose adjustments as needed, and provide an opportunity to address any side effects or concerns
